September 12th 2025
Ocaliva, approved for primary biliary cholangitis, faced FDA warnings and restrictions after postmarket data showed higher risks of liver transplant and death among treated patients.
FDA Warns of Liver Injury with Veozah for Hot Flashes
September 12th 2024The FDA has identified a probable case of serious drug induced liver injury that occurred in a woman in the United States who had received Veozah. The agency is requiring additional liver blood testing after starting therapy.
Read More